Damora Therapeutics, Inc. Common Stock’s (DMRA) “Outperform” Rating Reaffirmed at Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued on Tuesday, Benzinga reports. They presently have a $40.00 price target on the stock. Wedbush’s price target suggests a potential upside of 92.77% from the company’s current price.

Several other equities analysts have also recently commented on DMRA. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Guggenheim raised their price target on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Up 0.4%

Shares of NASDAQ DMRA opened at $20.75 on Tuesday. The company has a market cap of $1.28 billion, a P/E ratio of -6.16 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a 52 week low of $3.50 and a 52 week high of $38.33. The business has a 50-day simple moving average of $28.18 and a two-hundred day simple moving average of $26.27.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.06. Equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Insider Buying and Selling

In related news, CEO Jennifer Jarrett purchased 12,500 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the acquisition, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DMRA. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the second quarter worth $303,000. Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $260,000. Seven Fleet Capital Management LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $7,398,000. Finally, Braidwell LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $42,146,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.